Today’s Price Action: A Reversal for Alcobra Ltd Is Not Near. The Stock Rises Again

Today's Price Action: A Reversal for Alcobra Ltd Is Not Near. The Stock Rises Again

The stock of Alcobra Ltd (NASDAQ:ADHD) is a huge mover today! About 278,732 shares traded hands. Alcobra Ltd (NASDAQ:ADHD) has declined 47.00% since February 29, 2016 and is downtrending. It has underperformed by 59.21% the S&P500.
The move comes after 9 months positive chart setup for the $68.34M company. It was reported on Oct, 3 by Barchart.com. We have $3.86 PT which if reached, will make NASDAQ:ADHD worth $36.22 million more.

Alcobra Ltd (NASDAQ:ADHD) Ratings Coverage

Out of 6 analysts covering Alcobra (NASDAQ:ADHD), 3 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 50% are positive. Alcobra has been the topic of 11 analyst reports since August 9, 2015 according to StockzIntelligence Inc. Oppenheimer initiated it with “Outperform” rating and $16 target price in Monday, January 25 report. Barclays Capital initiated the stock with “Equal-Weight” rating in Monday, August 1 report. On Thursday, February 18 the stock rating was initiated by Jefferies with “Buy”. Zacks upgraded Alcobra Ltd (NASDAQ:ADHD) on Monday, August 17 to “Hold” rating. The firm has “Buy” rating by Roth Capital given on Thursday, February 4. On Tuesday, June 7 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock of Alcobra Ltd (NASDAQ:ADHD) has “Hold” rating given on Thursday, September 29 by Cantor Fitzgerald. WBB Securities maintained the shares of ADHD in a report on Sunday, August 9 with “Hold” rating. Roth Capital maintained the stock with “Buy” rating in Tuesday, June 21 report. TH Capital maintained the stock with “Buy” rating in Friday, August 14 report.

According to Zacks Investment Research, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment